secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001753926-25-001003
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange
--------------------------------------------------------------------------------

- Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.
- Common stock now quoted on OTC Pink Market under symbol LIPO; company remains fully reporting with SEC.
- CEO Jonathan Kaufman issued stockholder letter detailing plans to submit initial listing application to another national exchange.
- Clinical programs LP-310 (oral lichen planus) and LP-10 (hemorrhagic cystitis) continue unaffected; final LP-310 Phase 2a data expected H2 2025.
- Company states delisting was not due to financial instability and maintains sufficient capital for development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625001003/0001753926-25-001003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625001003/g084855_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer